Project Grant HT94252310393
Award Date
9/1/23
Completion Date
8/31/26
Dollars Obligated
$1.3M
Federal Agency
Defense Health Agency
Awardee
Duke University (TP7EK8DZV6N5)
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Durham, NC 27705, USA
Similar Awards
The Department of Defense's Defense Health Agency awarded a $241,500 Project Grant to Duke University under the Military Medical Research and Development (CFDA 12.420) program. The grant, awarded on September 1, 2025, supports research to understand the molecular communication between different types of prostate cancer cells. This fundamental research, to be conducted at Duke University in Durham, North Carolina, aims to transform healthcare for military service members, veterans, and the...
The U.S. Defense Health Agency awarded a $1,449,000 Project Grant to Duke University to conduct research aimed at "Identifying Essential Molecular Mechanisms for Advanced Prostate Cancer Growth by a New Chemical Compound." This grant is funded under the Department of the Army Medical Command's Military Medical Research and Development program (CFDA 12.420), which supports biomedical research to improve the health and care of military service members, veterans, and their families. The...
The federal Project Grant award of $481,158.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) enables Duke University to conduct research aimed at "Blocking Glutamine Utilization in Advanced and Therapy-Resistant Prostate Cancer." The award supports a two-year project from June 1, 2024 to May 31, 2026 to expand the frontiers of scientific knowledge and apply it to address a critical medical challenge facing military service...
The Defense Health Agency awarded Duke University a $1,167,250 Project Grant (CFDA 12.420 - Military Medical Research and Development) with a performance period from June 1, 2024 to May 31, 2027. The grant funding supports Duke's research on the role of the NLRP3-NLRC5 signaling pathway in melanoma immune evasion and dormancy. The research aims to advance the understanding of mechanisms underlying melanoma progression, with the potential to inform new therapeutic approaches. As a prominent...
The Department of Defense's Defense Health Agency awarded a $4,818,759 Project Grant to Duke University under the Military Medical Research and Development program (CFDA 12.420) for the project "SINGLE-CELL AND SPATIAL ANALYSIS OF LETHAL BREAST CANCERS". The grant, awarded on April 1, 2024, will fund research to improve understanding and treatment of lethal breast cancers through advanced single-cell and spatial analysis techniques. This work supports the program's goals of...
The Department of the Army Medical Command awarded Duke University a $482,890 Project Grant under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from April 1, 2022 to March 31, 2024 to target the oncogenomic function of the E2F8 transcription factor in lethal prostate cancer. Through this funding, Duke University researchers will investigate medical solutions for prostate cancer at the genomic level, with the aim of transforming healthcare for...
The Defense Health Agency awarded Duke University a $3,811,150.00 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to conduct a research project titled "SINGLE-CELL AND SPATIAL ANALYSIS OF LETHAL BREAST CANCERS". The grant period runs from April 1, 2024 to March 31, 2028. The key products and services to be delivered under this award include comprehensive single-cell and spatial analysis of breast cancer samples to characterize tumor heterogeneity...
Duke University was awarded a $931,969 project grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from July 1, 2023 to June 30, 2026 to develop epigenetic signatures to predict pathological nodal stage for de-escalation of axillary surgery in patients with clinically node-positive breast cancer. The research aims to transform patient care by investigating medical solutions that could help reduce the need...
The Defense Health Agency awarded Duke University a $402,500 Project Grant under the Military Medical Research and Development program (CFDA 12.420) for the period of June 1, 2023 through May 31, 2025. The grant will support Duke University's research efforts to target the ferropotosis protection mechanism of serum to disable cancer metastasis. The Military Medical Research and Development program aims to transform military and public health through innovative medical research solutions for both...
This Defense Health Agency Project Grant award of $1,204,899 to Duke University, with a period of performance from January 1, 2024 to December 31, 2027, supports targeted vaccination research to treat and prevent endocrine-resistant ER+ breast cancer. The project aims to develop new treatments by targeting common resistance genes and neoepitope mutations. This grant is funded through the Department of Defense's Military Medical Research and Development program (CFDA 12.420), which supports...